Arexvy: Cost, Dosage, Side Effects, and More

Arexvy sounds a bit like a sci-fi robot, but it is actually a vaccine designed to help protect adults from respiratory syncytial virus, better known as RSV. And yes, RSV is not just “that baby virus” people hear about during winter. In older adults and people with certain chronic medical conditions, RSV can turn from a sniffly inconvenience into a lower respiratory tract infection, bronchitis, pneumonia, hospitalization, or a very unwanted date with an oxygen monitor.

Arexvy is GSK’s adjuvanted RSV vaccine. It is given as a single intramuscular shot and is approved by the U.S. Food and Drug Administration to help prevent RSV-related lower respiratory tract disease in adults age 60 and older, as well as adults ages 18 through 59 who are at increased risk for RSV-related lower respiratory tract disease. CDC recommendations focus on a single RSV vaccine dose for all adults age 75 and older and adults ages 50 through 74 who have increased risk of severe RSV illness. That difference matters: FDA approval tells us who the product may be used for, while CDC recommendations often shape routine vaccination guidance and insurance coverage.

This guide breaks down Arexvy cost, dosage, common side effects, serious warnings, timing, eligibility, and practical experiences people may have when planning the shot. Think of it as your no-drama vaccine briefing, with fewer medical acronyms doing gymnastics across the page.

What Is Arexvy?

Arexvy is a prescription vaccine used to help prevent lower respiratory tract disease caused by RSV. Its generic description is respiratory syncytial virus vaccine, adjuvanted. It is a recombinant, non-live vaccine, meaning it does not contain live RSV and cannot give you RSV. Instead, it trains the immune system to recognize a key RSV protein so the body is better prepared if the virus shows up later acting like an uninvited winter houseguest.

The vaccine includes an adjuvant, a substance added to strengthen the immune response. In plain English, the adjuvant is like turning up the volume on the immune system’s training session. This is useful because immune responses can weaken with age or chronic illness, and RSV can be especially dangerous in adults with lung disease, heart disease, diabetes complications, kidney disease, liver disease, weakened immunity, or frailty.

Who May Be Eligible for Arexvy?

FDA-approved groups

Arexvy is approved in the United States for adults age 60 and older. It is also approved for adults ages 18 through 59 who are at increased risk for lower respiratory tract disease caused by RSV. Increased risk may include chronic cardiopulmonary disease, diabetes with complications, kidney disease, liver disease, neurologic or neuromuscular conditions that affect airway clearance, immune compromise, or other health factors that make respiratory infections more dangerous.

CDC-recommended groups

Current CDC adult RSV vaccine guidance recommends a single dose of RSV vaccine for all adults age 75 and older and for adults ages 50 through 74 who are at increased risk of severe RSV illness. The CDC does not currently describe RSV vaccination as an annual vaccine. In other words, this is not like the yearly flu shot where you automatically roll up your sleeve every fall because the calendar told you to.

For adults under 50, FDA approval and CDC routine recommendation may not always match perfectly at a given moment. People ages 18 through 49 with risk factors should talk with a healthcare professional and insurance plan before scheduling Arexvy, especially if cost or coverage is a concern.

How Much Does Arexvy Cost?

The list price for Arexvy in the United States is about $321 per single dose, according to GSK pricing information. However, list price is not always what a person pays at the pharmacy counter. Vaccine billing is the place where logic sometimes puts on roller skates: your final cost depends on insurance type, pharmacy network, provider billing, location, administration fees, and whether the vaccine is covered as a recommended preventive service.

Arexvy cost with Medicare

For people with Medicare Part D, recommended adult vaccines such as RSV vaccines are generally covered with no copay or deductible when requirements are met. Medicare Advantage plans that include drug coverage may also cover the vaccine through the plan’s drug benefit. The safest move is to call the pharmacy or plan before the appointment and ask, “Will my RSV vaccine be covered at this location with my plan?” It is not glamorous, but neither is discovering a surprise bill after you already rolled up your sleeve.

Arexvy cost with private insurance

Many people with employer-sponsored or privately purchased insurance may pay little or nothing for recommended vaccines when using an in-network provider. Still, private plans vary. Some require the vaccine to be given at a pharmacy; others may cover it at a doctor’s office. Some billing systems treat vaccines differently depending on whether they are processed through pharmacy benefits or medical benefits.

Arexvy cost without insurance

Cash prices often land around the low-to-mid $300 range, though retail prices can vary. Some pharmacy discount platforms list Arexvy prices around $320 to $370 for one dose, depending on location and coupon availability. People without insurance can ask pharmacies about current cash pricing, administration fees, and manufacturer assistance resources.

Arexvy Dosage: How Is It Given?

The standard Arexvy dosage is one 0.5 mL dose injected into a muscle, usually the deltoid muscle of the upper arm. A healthcare professional prepares the vaccine by combining the antigen component with the adjuvant component before giving the shot. After preparation, the vaccine should be used within the recommended time window and handled according to storage instructions.

Most eligible adults need only one dose at this time. CDC guidance says RSV vaccination is not currently annual, and people who already received an RSV vaccine generally should not receive another RSV vaccine dose unless future recommendations change. Ongoing research is looking at how long protection lasts and whether booster doses may be useful later.

When Is the Best Time to Get Arexvy?

Arexvy can be given at any time of year, but the best timing is usually late summer or early fall, before RSV begins spreading widely. In much of the continental United States, that often means August through October. RSV activity usually increases in fall and winter and may peak around December or January, although timing can vary by region.

If you missed the “perfect” window, do not assume you missed the bus entirely. A healthcare professional can help decide whether getting vaccinated later in the season still makes sense based on local RSV activity, your health risks, and whether you have already received an RSV vaccine.

Common Arexvy Side Effects

Most Arexvy side effects are mild to moderate and temporary. The most common reactions are exactly what many people expect after a vaccine: a sore arm, tiredness, muscle aches, headache, and joint pain. Your immune system is doing paperwork, and apparently it complains through your shoulder.

Common side effects in adults age 60 and older

• Injection site pain
• Fatigue
• Muscle aches
• Headache
• Joint pain

Common side effects in adults ages 50 through 59

• Injection site pain
• Fatigue
• Muscle aches
• Headache
• Joint pain
• Redness at the injection site
• Swelling at the injection site

Common side effects in adults ages 18 through 49

• Injection site pain
• Muscle aches
• Fatigue
• Headache
• Joint pain

These reactions usually improve within a few days. Rest, fluids, and using the injected arm normally can help. Some people choose to schedule the vaccine before a quieter day, especially if they know vaccines tend to make them feel like a phone battery stuck at 18%.

Serious Arexvy Side Effects and Warnings

Serious side effects are uncommon, but they matter. Arexvy should not be given to anyone with a history of severe allergic reaction, such as anaphylaxis, to any component of the vaccine. Vaccination sites should have appropriate medical treatment available in case of a severe allergic reaction.

Fainting can happen after injectable vaccines, especially in people prone to syncope. Sitting or lying down during and shortly after vaccination can reduce the risk of injury. If you have ever fainted after a shot, tell the pharmacist or clinician before they begin.

The prescribing information also includes a warning about Guillain-Barré syndrome, or GBS. Postmarketing data suggest an increased risk of GBS during the 42 days after vaccination with Arexvy. GBS is a rare neurologic condition that can cause weakness, tingling, and in severe cases paralysis. Anyone who develops unusual weakness, trouble walking, facial drooping, trouble swallowing, or severe tingling after vaccination should seek medical care promptly.

People with weakened immune systems may have a reduced immune response to Arexvy. That does not necessarily mean they should avoid it, but it does mean the decision should be individualized with a healthcare professional.

Who Should Talk to a Doctor Before Getting Arexvy?

Talk with a healthcare professional before receiving Arexvy if you have had a severe allergic reaction to a vaccine, have a bleeding disorder, take blood thinners, are immunocompromised, have a history of fainting after injections, or recently had another vaccine or acute illness. Mild illness is not always a reason to delay vaccination, but moderate or severe illness may lead a provider to reschedule.

Arexvy is not for use in pregnant individuals. For pregnancy-related RSV protection, a different RSV vaccine may be considered during a specific pregnancy window, depending on current guidance and individual circumstances. Breastfeeding individuals should also discuss RSV vaccination options with a clinician.

Arexvy vs. Other RSV Vaccines

There are multiple RSV vaccines for adults, including Arexvy from GSK, Abrysvo from Pfizer, and mResvia from Moderna. CDC guidance does not express a preference among available adult RSV vaccines for eligible adults age 50 and older. Availability, age indication, medical history, pharmacy stock, and insurance coverage may influence which one a person receives.

Arexvy is an adjuvanted recombinant vaccine. Abrysvo is a bivalent RSV prefusion F vaccine and is also used in pregnancy for infant protection under specific recommendations. mResvia is an mRNA RSV vaccine. The best option is not always the one with the flashiest science label; it is the one appropriate for the patient, available, covered, and recommended by the clinician.

How Effective Is Arexvy?

Clinical trial data in adults age 60 and older showed strong protection against RSV-related lower respiratory tract disease and severe RSV-related disease. Protection was evaluated in large studies that included adults with and without underlying medical conditions. Later approvals for younger at-risk adults were supported by immune response data showing that adults ages 18 through 59 at increased risk produced immune responses considered comparable to those seen in older adults.

No vaccine offers a magic force field. Arexvy lowers the risk of RSV-related lower respiratory tract disease, but breakthrough infection can still happen. People at high risk should still use common-sense respiratory precautions during RSV season: wash hands, improve ventilation, stay home when sick, avoid close contact with people who are ill, and consider masks in crowded indoor settings when respiratory viruses are spreading heavily.

Practical Tips Before Getting Arexvy

Check eligibility first

Before making an appointment, confirm whether you are in a recommended or approved group. Adults age 75 and older usually have the clearest CDC recommendation. Adults ages 50 through 74 should review risk factors with a healthcare professional. Adults ages 18 through 49 with risk factors should verify both clinical appropriateness and insurance coverage.

Ask about cost before the shot

Ask the pharmacy or clinic: “What will my out-of-pocket cost be today?” Also ask whether the vaccine is billed through pharmacy benefits or medical benefits. This tiny question can save large amounts of future irritation.

Plan around side effects

Because sore arm and fatigue are common, avoid scheduling Arexvy immediately before a major event, long drive, heavy workout, or heroic furniture-moving adventure. Most people do fine, but giving yourself a low-pressure day afterward is a smart move.

Real-World Experiences With Arexvy: What the Process May Feel Like

For many adults, the Arexvy experience begins with a conversation at a doctor’s office or pharmacy. A clinician may ask about age, lung disease, heart disease, diabetes complications, kidney disease, immune status, and past vaccine reactions. This screening can feel repetitive, but it helps determine whether RSV vaccination is recommended and whether Arexvy is an appropriate choice. People who are used to annual flu shots may be surprised to learn that RSV vaccination is currently a one-time dose, not a yearly ritual. That is usually the first “wait, really?” moment.

The cost experience can vary more than the medical experience. One person may show a Medicare Part D card and pay nothing. Another may have private insurance and need to use a specific in-network pharmacy. A third may be quoted a cash price in the $300 range and decide to compare pharmacies or ask about discounts. The best practical lesson is simple: confirm coverage before the appointment. Nobody wants their immune system and their wallet both feeling attacked on the same afternoon.

The actual shot is quick. Arexvy is injected into the upper arm muscle, similar to a flu shot or COVID-19 vaccine. Some people feel only a pinch; others describe a sore, heavy arm later in the day. The soreness may be more noticeable when lifting groceries, reaching for a seat belt, or trying to sleep on the vaccinated side. In other words, your shoulder may temporarily develop an opinion.

After the shot, many people go about their day normally. Others feel tired, achy, mildly feverish, or headache-prone for a day or two. These symptoms are usually manageable and short-lived. Drinking water, eating normally, and avoiding overexertion can help. People who have previously reacted strongly to vaccines may prefer to schedule Arexvy before a weekend or quiet day.

Caregivers often think about Arexvy differently. For an older adult with COPD, heart failure, or multiple chronic conditions, avoiding RSV complications can mean avoiding a cascade: cough, wheezing, urgent care, steroids, antibiotics, oxygen, hospitalization, and weeks of recovery. In that context, a sore arm may feel like a pretty reasonable trade. Still, the decision should not be rushed. The best experience usually happens when the patient, caregiver, pharmacist, and clinician are all on the same page.

Another common experience is confusion about timing with other vaccines. Many adults are also considering flu, COVID-19, shingles, pneumonia, or Tdap vaccines. RSV vaccines can be given with other adult vaccines, but side effects may be more noticeable when shots are combined. Some people prefer one visit for convenience; others space vaccines out so they can tell which shot caused which side effect. Both approaches can be reasonable depending on medical needs and scheduling.

The most important experience is the follow-up mindset. Mild symptoms are expected, but severe allergic symptoms, unusual weakness, trouble breathing, trouble walking, or neurologic symptoms after vaccination should be taken seriously. Reporting concerning reactions helps vaccine safety systems monitor real-world outcomes. Vaccines are not “set it and forget it” science; they are continuously watched, studied, and updated.

Conclusion

Arexvy is an important RSV prevention option for adults who face higher risk from respiratory infections. It is given as a single 0.5 mL intramuscular dose, usually before RSV season, and it is not currently recommended as an annual vaccine. The most common Arexvy side effects include injection site pain, fatigue, muscle aches, headache, and joint pain. Serious reactions are rare but include severe allergic reaction and a warning about Guillain-Barré syndrome in the weeks after vaccination.

Cost depends heavily on insurance. The U.S. list price is about $321 per dose, while cash prices may vary by pharmacy. Medicare Part D generally covers recommended RSV vaccination with no out-of-pocket cost. Private insurance coverage is often favorable when using the right provider, but checking ahead is wise.

Note: This article is for educational purposes only and is not a substitute for professional medical advice. Vaccine recommendations, coverage rules, and product indications can change. Always ask a licensed healthcare professional whether Arexvy is appropriate for your age, health conditions, pregnancy status, allergy history, and insurance situation.